Energy Vault preps to go public, could raise $388M
Westlake Village-based Energy Vault disclosed details of its financial performance for the first time in an Oct. 18 filing with the U.S. Securities and Exchange Commission, filed in advance of its public stock offering and its pending merger with a special purpose acquisition company. Energy Vault, a green energy storage company, agreed to go public Read More →
Citizens Business Bank reports ‘solid loan growth,’ higher earnings in Q3
CVB Financial Corp., the parent company of Citizens Business Bank, saw an increase in net income and asset growth for the quarter ended Sept. 30 when compared to the same period last year. Headquartered in Ontario, California, Citizens Business Bank has four branches in Ventura County and one in Santa Barbara. The bank had net Read More →
Earnings, assets both up at Pacific Premier Bank
Pacific Premier Bancorp saw its net income and assets grow in its most recent quarter, the company announced Oct. 21. The Irvine-based bank, which has nine branches in Santa Barbara and San Luis Obispo counties, reported net income of $90.1 million, or 95 cents per diluted share, for the quarter ended Sept. 30. For the Read More →
Pacific Western Bank reports year-over-year earnings growth
Los Angeles-based PacWest Bancorp, which has 13 branches in the tri-county region, reported net earnings for the third quarter that were higher than a year before, but down from the previous quarter. In an Oct. 18 release, PacWest Bancorp, the parent company for Pacific Western Bank, reported net earnings of $140 million, or $1.17 per Read More →
MannKind shares drop 18% after FDA says it will pass on new blood pressure drug
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →
Amgen’s investment in Neumora marks a return to neuroscience research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen goes full speed ahead on biosimilar drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
